Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 8—August 2004

Research

Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient Management

Deborah S. Yokoe*Comments to Author , Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA

Main Article

Table 3

Detecting tuberculosis (TB) cases by using pharmacy screening and state health department TB registries

Case identification Plan A (%) Plan B (%) Plan C (%) Total (%)
Pharmacy screening only 3 (6) 1 (5) 9 (7) 13 (6)
State health department only (all cases) 38 (72) 15 (68) 80 (61) 133 (64)
State health department only (health plan–treated patients) 16 (52) 2 (22) 0a 18 (19)
Both methods 12 (22) 6 (27) 43 (32) 61 (30)
Total (all cases) 53 22 132 207
Total (health plan–treated patientsb) 31 9 52 92

aExtrapolated from review of a random sample of 28 of the 80 TB cases identified by the state health department and not by pharmacy screening.
bExcludes TB patients receiving anti-TB medication from public health clinics; these medications are not included in the health plan pharmacy databases.

Main Article

TOP